BJL
CHRS icon

Brighton Jones LLC’s Coherus Oncology CHRS Stock Holding History

Brighton Jones LLC’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9K Buy
+12,803
New +$20.9K ﹤0.01% 1405

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
TWP
Tyche Wealth Partners Plano, Texas $712M AUM 29.07% 1-Year Est. Return

Brighton Jones LLC's CHRS Position: Q2 2026 in Review

Brighton Jones LLC opened a new position in Coherus Oncology (CHRS) in Q2 2026: 12,803 shares worth $17.9K. The stake represents ﹤0.01% of the portfolio and ranks #1405 among its holdings.

69 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Brighton Jones LLC held 12,803 shares of Coherus Oncology worth $17.9K as of Q2 2026.
  • Coherus Oncology was a new Brighton Jones LLC position in Q2 2026.
  • Coherus Oncology made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1405 holding.
  • 69 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.